Navigation Links
Optimer Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
Date:5/3/2012

SAN DIEGO, May 3, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Company will present at the Bank of America Merrill Lynch 2012 Health Care Conference on Thursday, May 17 at 10:00 AM Pacific Time in Las Vegas, NV.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

A live audio webcast of the presentation will be accessible on the Investors page of the Company's website at www.optimerpharma.com.  Replays of the presentation will be available at the same location for 90 days following the presentation.

About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed and commercialized DIFICID® (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer has also received marketing authorization for fidaxomicin tablets in the European Union under the trade name DIFICLIR™. The company is seeking marketing authorization for fidaxomicin in Canada and is exploring marketing authorization in other parts of the world where C. difficile has emerged as a serious health problem, including Asia. Additional information can be found at http://www.optimerpharma.com.

Contacts
Optimer Pharmaceuticals, Inc.
David Walsey, VP of Investor Relations and Corporate Communications
858-964-3418

Canale Communications
Jason I. Spark, Senior Vice President
619-849-6005


'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
11. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... INCLINE VILLAGE, Nev. , July 28, 2014 ... announced that the Company will release its second quarter 2014 ... Monday, August 11, 2014, after market close. PDL,s management will ... p.m. Eastern Time to discuss the financial results.  A slide ... webcast link on the PDL website. Conference Call ...
(Date:7/28/2014)... , Germany and ... , Collaboration aims to create and ... to guide the use of IRESSA  for non-small cell ... build on QIAGEN,s FDA-approved  therascreen   EGFR test and is ... of automated instruments  Project enabled by AstraZeneca ...
(Date:7/25/2014)... HILL, N.C. , July 25, 2014  Corporate ... challenges, including understanding new advancements in technology and how ... of this, libraries in the pharmaceutical and medical device ... value of the information and services they provide. ... Best Practices, LLC there are many forces of change ...
Breaking Medicine Technology:PDL BioPharma to Announce Second Quarter 2014 Financial Results on August 11, 2014 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 3QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 4QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 5QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 6Forces of Change Reshaping Corporate Libraries & Information Services 2
... on 01/05/2012 of Santa Barbara physician Dr. Julio Diaz ... overdose deaths from prescription medications. According to one of ... centers, Dr. Diaz,s arrest points to the dangers both ... of finding a physician who will prescribe medication for ...
... PHILADELPHIA, January 10, 2012 Shire plc (LSE: ... company, announced today that it has acquired the rights to ... States (US) in an agreement  with Janssen Pharmaceutica N.V.  Terms ... a prokinetic, is part of Shire,s gastrointestinal (GI) portfolio in ...
Cached Medicine Technology:Arrest of California Doctor Coincides with Uptick in Prescription Drug Overdoses 2Shire Acquires US Rights to Resolor® (prucalopride) 2Shire Acquires US Rights to Resolor® (prucalopride) 3Shire Acquires US Rights to Resolor® (prucalopride) 4
(Date:7/28/2014)... researchers in Taiwan has developed a new optical technology ... of diabetes sooner, when it is more easily treated. ... trials, it may pave the way for the early ... diabetic autonomic neuropathy, which is common among people with ... progressively affects the autonomic nerves controlling vital organs like ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Top Northridge ... coupon for new patients. Finding a new dentist can be ... dental issues that have gone untreated and worry about how ... Ariz specializes in patients with special concerns and dental needs ... comfortable and right at home. This special coupon can help ...
(Date:7/28/2014)... July 28, 2014 "I injured my shoulder ... said an inventor from Sunnyvale, Calif. "When I slept in ... the market are cumbersome and require too many straps. That ... developed the Multiple Functioning Vest to improve the design of ... so that they heal properly. This helps to speed up ...
(Date:7/28/2014)... HealthDay Reporter FRIDAY, July ... health insurance this year will face fines of up to ... the Internal Revenue Service says. The Obama administration on ... that some Americans will owe for failing to have health ... monthly national average premium for a bronze-level health plan. ...
(Date:7/28/2014)... 2014 Glidewell Laboratories announced today that ... successfully passed the five-year mark in clinical usage, and ... units prescribed by US dentists. , Even as BruxZir ... good results from respected clinical studies, many dentists expressed ... over extended years of clinical service before they would ...
Breaking Medicine News(10 mins):Health News:Wearable device for the early detection of common diabetes-related neurological condition 2Health News:Northridge Dentist, Dr. Farshid Ariz, is Now Offering a $100 Coupon for New Patients 2Health News:IRS Caps Fines on Uninsured Americans at $12K for Family of 5 2Health News:BruxZir® Solid Zirconia Surpasses Five Years of Clinical Use 2
... , HARRISBURG, Pa. , Jan. 13 ... launch of an innovative initiative to create clinically proven, ... of care for patients.  The P4 Pathways Program will ... for the treatment of patients with cancer, as well ...
... , NEW YORK , Jan. 13 ... been named president and CEO of Siemens Corporation. Spiegel, an ... on January 18 . , (Logo:   http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO ... Senior Partner at Booz & Co. and brings more than ...
... Bradley C. Brennecke , a resident of Pleasant Plain, Ohio ... , pleaded guilty late Tuesday to conspiracy and tax evasion charges before District ... Department and Internal Revenue Service (IRS) announced. , Mrusek and Brennecke, who ... icted in July 2009 and charged with tax ...
... in the general population use the drug responsibly, study finds ... taking Viagra will lead to sexually risky behavior can relax: ... make men more likely to engage in potentially unhealthy sex. ... a doctor who may worry that prescribing erectile-dysfunction drugs to ...
... say researchers working with mice , WEDNESDAY, Jan. 13 ... greater understanding of how a brain becomes susceptible to ... some people are resistant to antidepressants. , Scientists think ... -- cause the mental disorders. Antidepressants (such as Prozac) ...
... aged 6-19 still climbing, government study finds , WEDNESDAY, Jan. ... on weight: Obesity in the United States may finally be ... the rates of obesity remain high, with about one-third of ... obesity among already heavy 6- to 19-year-old boys appear to ...
Cached Medicine News:Health News:Capital BlueCross and P4 Healthcare Launch Cancer Pathways Initiative 2Health News:Capital BlueCross and P4 Healthcare Launch Cancer Pathways Initiative 3Health News:Capital BlueCross and P4 Healthcare Launch Cancer Pathways Initiative 4Health News:Siemens Taps Top Energy Expert as New Head of U.S. Business 2Health News:Siemens Taps Top Energy Expert as New Head of U.S. Business 3Health News:Two Cincinnati Dentists Plead Guilty to Conspiracy, Tax Evasion on Eve of Trial 2Health News:Taking Viagra Won't Spur Risky Sexual Behavior 2Health News: U.S. Obesity Rates Leveling Off, But Still High 2Health News: U.S. Obesity Rates Leveling Off, But Still High 3
Duckbill. 3.5 mm tip. Light curve....
4 mm x 9 mm tip....
6 mm wide tip. Gentle tapered blade. Designated most popular model or size....
9 mm wide tip. 35 mm from angle to tip....
Medicine Products: